ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 08 4:00PM
Realtime Data

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
ImjinBridger ImjinBridger 1 minute ago
No update on Cambodia?[/quote
Cambodia is just a rumor started by someone on this board. Wouldn't hold my breath for an update on a rumor.
KBLB
Zorax Zorax 2 minutes ago
Works fine for me, never seen a problem.
Clear your cache?
dbergh dbergh 3 minutes ago
, Closed mind, confirmed bigot. Ok.


https://youtu.be/r9URPvejWHk?si=boCiLsAUQEUMxXkZ
Kool Aid Man Kool Aid Man 3 minutes ago
Eddie announced this WAWA gold BS in January..despite yapping about it all year AURI has been rotting at .0001
https://www.otcmarkets.com/otcapi/company/dns/news/document/72369/content

He's made over 600 PR's just on OTC alone not to mention on paid newswire services. Here's th
AURI
mascale mascale 3 minutes ago
I myself even do plant-based meat, reversing in that manner kidney failure. The pitiful deflection from the Jack_Herer over-stated slur and slam of OTC--USA, anyone can now note. Inferences can be noted. The international standing of Qatar--many can now say: Is even on-board with audited financi
HIRU
waterchaser waterchaser 3 minutes ago
He doesn’t know so he won’t respond.
Huzza (or whatever it is that he posts incessantly).
DJT
gp22 gp22 4 minutes ago
$MTEK: Supplies the AI that power $MOB, $PRZO, $LBTH and other companies that need AI. $MTEK the last AI Drone play to get found. Nano-float $MTEK AI also powers tanks, armored vehicles and many cicilian uses. $MTEK just opened a USA Division too.
LBTH MOB MTEK
gp22 gp22 4 minutes ago
$MTEK: Supplies the AI that power $MOB, $PRZO, $LBTH and other companies that need AI. $MTEK the last AI Drone play to get found. Nano-float $MTEK AI also powers tanks, armored vehicles and many cicilian uses. $MTEK just opened a USA Division too.
LBTH MOB MTEK
georgejjl georgejjl 4 minutes ago
Monksdream,

It is the fiscal 10K that is due Thursday 12 December NOT a 10Q.

Good luck and GOD bless,
AVXL
1vman 1vman 4 minutes ago
*****🟥🟥🟥 Short story long 🚽DBMM🚽 is a failing company for 20 years thats going down hill fast ! -- Wh👀ps !

ENOUGH SAID HUZZAH🤪 !!!
DBMM
Lime Time Lime Time 4 minutes ago
Most shareholders must be in around .01 or .02, I'm thinking, so for this to go up to .25 or beyond is not without reach. A hot market is underway
GVSI
Goldenboy17 Goldenboy17 4 minutes ago
Great to hear the excavation of the area below the teredo crust is being filmed and documented.

Bet there is a good reason for that.

Just like there is a good reason for the family holding on to over a billions shares of SFRX for years.

Insiders not se
SFRX
gp22 gp22 5 minutes ago
$MTEK: Supplies the AI that power $MOB, $PRZO, $LBTH and other companies that need AI. $MTEK the last AI Drone play to get found. Nano-float $MTEK AI also powers tanks, armored vehicles and many cicilian uses. $MTEK just opened a USA Division too.
LBTH MOB MTEK
1vman 1vman 5 minutes ago
***** 💩HCWC💩 BUYER BEE WARE !!! Zero proof GreensNaturalFoods doubled Revenues to 73 Million

Fins do NOT confirm this - Wh👀ps

HUZZAH🤔 !!! ENOUGH SAID🤔 !!!
HCWC
yadotn yadotn 7 minutes ago
MRNJ>>>NofungusAmongus>>>Foundation>>>(370,481)

MRNJ
OTCMarkets
Press Release
October 13, 2021
"“We are very excited about the growth and opportunity NFT segments of Crypto and E-commerce provide, while forming the foundation of the new virtual economy” Ral
MRNJ
Drugdoctor Drugdoctor 7 minutes ago
Agree 100% on that!
GVSI
Guido2 Guido2 7 minutes ago
Doesn't explain why you want $90 target to be divided by 16. I personally feel it's too low based on their earnings history the last 10 years and their current books of business.
FNMA
StockItOut StockItOut 7 minutes ago
Santelli of Basile Law Firm on behalf of Xeriant argued that Quester is an idiot.
XERI
Zorax Zorax 8 minutes ago
Please define MOASS please.
DJT
DAR53 DAR53 9 minutes ago
JRoon, sometimes you make sense and other times you seem to be so negative. I would think that if the injunction is successful it may begin to scare the sh t out of some of the other generics. There is still a lot to be done legally to slow down or stop sales of GV.
Nobody responded to my
AMRN

Your Recent History

Delayed Upgrade Clock